Cerebriu Apollo Brain
CerebriuProduct specifications |
Information source:
Vendor
Last updated: July 5, 2022 |
General | |
---|---|
Product name | Cerebriu Apollo Brain |
Company | Cerebriu |
Subspeciality | Neuro |
Modality | MR |
Disease targeted | Infarcts (except chronic), intracranial tumors (except iso-intense on T2 FLAIR), and intracranial hemorrhages (except isolated intraventricular hemorrhages, microhemorrhages, or those that are not hypointense on SWI/T2* GRE). |
Key-features | Vizualization of criticial brain pathology candidate findings, real-time results enabling MR protocol adaptation |
Suggested use | During: perception aid (prompting all abnormalities/results/heatmaps), interactive decision support (shows abnormalities/results only on demand) |
Data characteristics | |
Population | Patients between 15 and 75 years receiving brain MR |
Input | FLAIR, diffusion, T2*/SWI or equivalent |
Input format | DICOM |
Output | Detection of candidates finding larger than 5 mm3, image annotations |
Output format | DICOM SC |
Technology | |
Integration | Integration via AI marketplace or distribution platform, Stand-alone third party application, Stand-alone webbased, Embedded on the MRI console |
Deployment | Locally on dedicated hardware, Cloud-based, Hybrid solution |
Trigger for analysis | Automatically, while the patient is in the scanner |
Processing time | 1 - 10 minutes |
Certification | |
CE
|
Certified,
Class I
, MDD
|
FDA
|
No or not yet |
Market presence | |
On market since | 05-2021 |
Distribution channels | |
Countries present (clinical, non-research use) | |
Paying clinical customers (institutes) | |
Research/test users (institutes) | |
Pricing | |
Pricing model | Subscription |
Based on | Number of users, Number of installations, Number of analyses |
Evidence | |
Peer reviewed papers on performance | |
Non-peer reviewed papers on performance | |
Other relevant papers |